Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

52.51USD
15 Dec 2017
Change (% chg)

$-0.35 (-0.66%)
Prev Close
$52.86
Open
$52.06
Day's High
$52.65
Day's Low
$52.02
Volume
1,766,290
Avg. Vol
1,853,878
52-wk High
$53.49
52-wk Low
$32.83

Latest Key Developments (Source: Significant Developments)

EU Medicines Agency Recommendations For December 2017 ‍​
Friday, 15 Dec 2017 07:19am EST 

Dec 15 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY RECOMMENDATIONS FOR DECEMBER 2017 ‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF NOVO NORDISK'S ONCE-WEEKLY DIABETES DRUG SEMAGLUTIDE‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF KYOWA HAKKO KIRIN DRUG FOR GENETIC BLOOD DISORDER XLH BUROSUMAB.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF TIGENIX'S STEM CELLS TREATMENT FOR PERIANAL FISTULAS ALOFISEL.  Full Article

reMYND Enters Into License Agreement with Novo Nordisk​
Thursday, 14 Dec 2017 01:30am EST 

Dec 14 (Reuters) - reMYND::REMYND-UNDER AGREEMENT,CO COULD RECEIVE UP TO 350 MILLION EUROS IN RESEARCH AND MILESTONE PAYMENTS,PLUS ROYALTIES ON RESULTING NET SALES.REMYND ENTERS INTO LICENSE AGREEMENT TO FURTHER DEVELOP NOVEL TREATMENTS IMPROVING BETA-CELL HEALTH AND INSULIN SIGNALLING WITH NOVO NORDISK​.  Full Article

Prime Therapeutics Says Co, Novo Nordisk To Establish Value-Based Contract For Type 2 Diabetes Drug Victoza
Friday, 8 Dec 2017 09:10am EST 

Dec 8 (Reuters) - Novo Nordisk A/S ::PRIME THERAPEUTICS - CO, NOVO NORDISK TO ESTABLISH A VALUE-BASED CONTRACT FOR TYPE 2 DIABETES DRUG, VICTOZA.  Full Article

Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018
Wednesday, 6 Dec 2017 06:25am EST 

Dec 6 (Reuters) - NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC::STILL EXPECTS TO LAUNCH OZEMPIC DIABETES DRUG IN JAPAN DURING THE FIRST HALF OF NEXT YEAR."WHEN IT COMES TO THE JAPANESE SITUATION WE ARE STILL EXPECTING TO MEET UP WITH THE COMMITTEE DURING THE COURSE OF JANUARY AND THEN BE ABLE TO WRAP UP THE LABEL, SO WE ARE EXPECTING ... TO LAUNCH DURING THE COURSE OF THE FIRST OF HALF OF NEXT YEAR ALSO IN JAPAN"."IN EUROPE WE SHOULD HOPE THAT THE ENDORSEMENT IS GIVEN BY THE CHMP (COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE) DURING THE MONTH OF DECEMBER".THE U.S. FOOD AND DRUG ADMINISTRATION ON TUESDAY APPROVED NOVO'S DIABETES DRUG OZEMPIC, SETTING THE STAGE FOR A HEATED BATTLE WITH ELI LILLY & CO'S <<>> TRULICITY nL1N1O51MY.  Full Article

Novo' Xultophy reported as better option than basal-bolus insulin therapy to manage type 2 diabetes
Tuesday, 5 Dec 2017 01:13am EST 

Dec 5 (Reuters) - NOVO NORDISK A/S ::XULTOPHY REPORTED A BETTER OPTION THAN BASAL-BOLUS INSULIN THERAPY TO MANAGE TYPE 2 DIABETES BY PARTICIPANTS IN THE DUAL VII CLINICAL TRIAL.THIS WAS REPORTED BY PEOPLE WITH TYPE 2 DIABETES WHOSE BLOOD SUGAR WAS NOT CONTROLLED ON INSULIN GLARGINE U100 WITH METFORMIN, AND WHO COMPLETED QUALITY-OF-LIFE QUESTIONNAIRES AS PART OF THE DUAL VII CLINICAL TRIAL.MORE PEOPLE PREFERRED TO STAY ON XULTOPHY COMPARED WITH BASAL-BOLUS THERAPY (84.5 PCT VERSUS 68.1 PCT).RESULTS WERE PRESENTED AT THE 2017 INTERNATIONAL DIABETES FEDERATION CONGRESS IN ABU DHABI, UAE..  Full Article

Novo Nordisk's Xultophy offers greater weight reductions than Iglarlixi
Monday, 4 Dec 2017 01:59am EST 

Dec 4 (Reuters) - NOVO NORDISK SAYS::XULTOPHY CAN DELIVER GREATER REDUCTIONS IN THE OVERALL BLOOD SUGAR LEVELS AND WEIGHT FOR PEOPLE WITH TYPE 2 DIABETES WHO ARE UNCONTROLLED ON BASAL INSULIN, COMPARED TO IGLARLIXI.NEW FINDINGS ARE FROM AN INDIRECT COMPARISON BETWEEN XULTOPHY AND IGLARLIXI PUBLISHED IN THE JOURNAL OF MEDICAL ECONOMICS .THE ANALYSIS IS BASED ON PUBLISHED DATA FROM INDIVIDUAL CLINICAL TRIALS WHICH INVOLVED OVER 700 ADULTS LIVING WITH TYPE 2 DIABETES.PEOPLE WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN ACHIEVED A 0.44 PCT GREATER REDUCTION OF THEIR OVERALL BLOOD SUGAR LEVELS (HBA(1C)), AND A 1.42 KG GREATER WEIGHT LOSS WHEN TREATED WITH XULTOPHY, COMPARED TO THOSE TREATED WITH IGLARLIXI, AT SIMILAR DOSES OF INSULIN. .  Full Article

Health Canada approves update for Novo Nordisk's Victoza
Tuesday, 21 Nov 2017 08:00am EST 

Nov 21 (Reuters) - Novo Nordisk :Says Health Canada has approved a product monograph update for Victoza (liraglutide)​.  Full Article

Novo Nordisk updates on research and strategy
Tuesday, 21 Nov 2017 02:00am EST 

Nov 21 (Reuters) - NOVO NORDISK SAYS AHEAD OF CAPITAL MARKETS DAY:‍AMBITION IS TO FURTHER EXPAND LEADERSHIP IN GLOBAL DIABETES AND OBESITY CARE MARKETS BY DISCOVERING, DEVELOPING AND MARKETING IMPROVED INSULIN AND GLP-1 ANALOGUES AS WELL AS COMPLETELY NEW CLASSES OF BIOLOGICS​.‍AMBITION TO RETURN TO GROWTH IN BIOPHARM AREA​.‍IN PIONEER PHASE 3A CLINICAL TRIAL PROGRAMME FOR ORAL SEMAGLUTIDE ALL 10 TRIALS IN PROGRAMME ARE EXPECTED TO BE COMPLETED IN 2018​.‍FOLLOWING COMPLETION OF PHASE 3A CLINICAL TRIAL PROGRAMME FOR ONCE-DAILY ORAL SEMAGLUTIDE, COMMERCIAL FOCUS WILL BE DIRECTED TOWARDS LAUNCHING IN MAJOR GEOGRAPHIES ASSUMING A SUCCESSFUL CLINICAL AND REGULATORY PROCESS.​.‍PLANS TO INITIATE A PHASE 3A CLINICAL DEVELOPMENT, STEP, WITH ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE IN 2018​.‍IS ALSO PLANNING TO INITIATE A LANDMARK CARDIOVASCULAR OUTCOME TRIAL IN 2018 WITH ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE IN OBESITY​.  Full Article

Novo Nordisk CEO says still looking for biopharma bolt-on acquisitions
Wednesday, 1 Nov 2017 08:09am EDT 

Nov 1 (Reuters) - NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN MADE FOLLOWING COMMENTS ON AN ANALYST CALL::"WE'RE LOOKING TO BOLT ON EXTERNAL INNOVATION IN OUR BIOPHARMA BUSINESS ... WE'RE WORKING ON IT BUT THIS IS SOMETHING THAT TAKES TIME".  Full Article

Novo Nordisk Q3 EBIT DKK 12.04‍​ bln, slightly higher than expected
Wednesday, 1 Nov 2017 02:30am EDT 

Nov 1 (Reuters) - NOVO NORDISK :Q3 SALES ‍​26.6 BILLION DKK VERSUS 27.24 BILLION DKK SEEN IN REUTERS POLL.Q3 OPERATING PROFIT 12.04‍​ BILLION DKK VERSUS 11.95 BILLION DKK SEEN IN REUTERS POLL.9-MONTH SALES ‍83.7​ BILLION DKK VERSUS 84.33 BILLION DKK SEEN IN REUTERS POLL.9-MONTH OPERATING PROFIT ‍38.9​ BILLION DKK VERSUS 38.82 BILLION DKK SEEN IN REUTERS POLL.SAYS ‍PRELIMINARY OUTLOOK FOR 2018 IN LOCAL CURRENCIES INDICATES LOW TO MID SINGLE-DIGIT GROWTH IN BOTH SALES AND OPERATING PROFIT​.SAYS ‍SALES GROWTH REPORTED IN DANISH KRONER IS EXPECTED TO BE 3 PERCENTAGE POINTS LOWER THAN IN LOCAL CURRENCIES, AND REPORTED OPERATING PROFIT GROWTH IS EXPECTED TO BE 4 PERCENTAGE POINTS LOWER​.SAYS ‍FINANCIAL OUTLOOK FOR 2017 HAS BEEN UPDATED AND SALES GROWTH MEASURED IN LOCAL CURRENCIES IS NOW EXPECTED TO BE IN RANGE OF 2% TO 3% COMPARED WITH PREVIOUS RANGE OF 1% TO 3%​.SAYS ‍OPERATING PROFIT GROWTH MEASURED IN LOCAL CURRENCIES IS NOW EXPECTED TO BE IN RANGE OF 3% TO 6% COMPARED WITH PREVIOUS RANGE OF 1% TO 5%​.NOVO NORDISK CEO: ‍WE CONTINUE TO DELIVER ON OUR PLANS FOR 2017​.SAYS NEGATIVE CURRENCY IMPACT OF 3 PERCENTAGE POINTS ON OPERATING PROFIT GROWTH IS NOW EXPECTED FOR 2017.SAYS CAPITAL EXPENDITURE IS NOW EXPECTED TO BE AROUND DKK 9 BILLION IN 2017.  Full Article

Novo Nordisk wins EU panel's backing for key diabetes drug

COPENHAGEN Danish drugmaker Novo Nordisk came closer to winning European approval for diabetes drug Ozempic, its biggest growth prospect, when a European Medicines Agency (EMA) experts' panel issued a positive recommendation on Friday.